DSIP
Sleep Research only Human trials
Also called Delta sleep-inducing peptide, Emideltide
A nine-amino-acid peptide first isolated in the 1970s from rabbits in deep sleep. Beyond sleep patterns, it has been studied for effects on stress hormones, pain perception and blood pressure. Results across studies are mixed, and how it works is still unclear.
Evidence at a glance
- Evidence
- Human trials — Studied in people
- Status
- Research compound only
- Dosing
- A dose has been tested in humans
Human studies are from the 1980s-90s, small, and inconsistent; several found no effect.
What studies report
- Shorter time to fall asleep and better sleep quality in small older studies of poor sleepers
- Reduced reported pain in a small chronic pain study
- Changes in cortisol and growth hormone release
How it works
Not well established, which is part of why results are inconsistent. It is reported to modulate corticotropin and somatostatin release and to influence sleep architecture, but no clear receptor has been identified.
Where it acts
BrainThe library groups this compound under Sleep. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
In practice Unapproved use
- Used intermittently before bed rather than nightly
- Results are inconsistent enough that the community is openly divided on whether it works
Reported real-world use, not evidence and not a recommendation.
Dosing
What was tested Evidence
- 25 nmol/kg, intravenousSmall 1980s–90s sleep and chronic pain studies→ Mixed; several found no effect
What people report using Not evidence
- 100–300 mcg before bed, used intermittently
The community is openly divided on whether it does anything.
Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.
Status: Small, older human studies. Not approved.
- Route
- Subcutaneous injection, from reconstituted lyophilised powder
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Formula
- C35H48N10O15
- Molecular weight
- 848.8 g/mol
- CAS
- 62568-57-4
- Available as
- 5 mg
Search PubMed for DSIP → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.